Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer

Study limitation reported by the research below: “The impact flag 'safety signal' is used loosely here to flag prognostic risk heterogeneity — this is not a drug safety/adverse event signal in the traditional sense.”